AUC	area under the curve
CCK1R	cholecystokinin type 1 receptor
CXCR4	C-X-C chemokine receptor type 4
DAB	diaminobutyric acid
DOTA	1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
DOTAGA	1,4,7,10-tetraazacyclododececane-1-(glutaric acid)-4,7,10-triacetic acid
EB	Evans Blue
EMA	European Medicines Agency
FAP	fibroblast activation protein
FAPI	fibroblast activation protein inhibitor
FDA	Food and Drug Administration
GFK	glycine phenylalanine-lysine
GLP-1R	glucagon-like peptide-1 receptor
GY	glycine-tyrosine
HBED-CC	N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid
HE	histidine-glutamic acid
Her2/neu	human epidermal growth factor receptor 2
HYNIC	hydrazinonicotinic acid
kDa	kilodalton
mAb	monoclonal antibody
MAG3	mercaptoacetylglycylglycylglycin
MC1R	melanocortin-1 receptor
mCRPC	metastatic castration resistant prostate cancer
α-MSH	melanocyte stimulating hormone
MVK	methionine-valine-leucine
NEP	neutral endopeptidase
NODAGA	1,4,7-triazacyclononane-1-(glutaric acid)-4,7-diacetic acid
NOTA	1,4,7-triazacyclononane-1,4,7-triacetic acid
NOTA-p-SCN	S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid
PEG	polyethylene glycol
PET	positron emission tomography
PGA	polyglutamic acid
p.i.	post injection
PSMA	prostate specific membrane antigen
RGD	arginine-glycine-aspartic acid
sdAb	single-domain antibody-fragment
SPECT/CT	single photon emission computed tomography/computed tomography
TE2A	1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid
TRT	targeted radionuclide therapy
uPAR	urokinase-type plasminogen receptor